Preferred Label : Paritaprevir;
NCIt synonyms : (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo
[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide; Veruprevir;
NCIt definition : An orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus
(HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with
potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly
binds to the active center and binding site of the HCV NS3/NS4A protease and prevents
NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing
of viral proteins and the formation of the viral replication complex, which inhibits
viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is
essential for the proteolytic cleavage of multiple sites within the HCV polyprotein
and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating
factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to
the Flaviviridae family, and infection is associated with the development of hepatocellular
carcinoma (HCC).;
UNII : OU2YM37K86;
InChIKey : UAUIUKWPKRJZJV-QPLHLKROSA-N;
CAS number : 1216941-48-8;
Molecule name : ABT 450; ABT-450;
Origin ID : C123879;
UMLS CUI : C3864824;
Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
